Compare SWRD & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWRD | EOLS |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 593.4M | 500.0M |
| IPO Year | 2025 | 2018 |
| Metric | SWRD | EOLS |
|---|---|---|
| Price | $3.14 | $7.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 238.9K | ★ 669.7K |
| Earning Date | 11-17-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $12.44 |
| Revenue Next Year | N/A | $17.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $1.79 | $3.86 |
| 52 Week High | $3.57 | $9.31 |
| Indicator | SWRD | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 44.48 |
| Support Level | $2.26 | $6.99 |
| Resistance Level | $3.57 | $7.28 |
| Average True Range (ATR) | 0.35 | 0.35 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 68.16 | 38.71 |
Stewards Inc is a diversified financial services company with two complementary business platforms: Private Credit and Real Estate. It provides alternative financing solutions to small and medium-sized businesses (SMBs) underserved by traditional lenders, while also building a portfolio of income-producing and value enhancing real estate assets. The Private Credit Division provides revenue-based funding and related financing products to SMBs nationwide. The Real Estate Division targets strategic investments in residential, mixed-use, and commercial properties designed to generate stable rental income and have the potential for long-term value appreciation. It operates in two segments Financing Solutions, and Real Estate Operations.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.